What is GLOW used for?

GLOW is supplied strictly for in-vitro and laboratory research. It is not an approved medicine and is not intended for human consumption. No clinical study has tested the GLOW blend itself.

What is the difference between GLOW and KLOW?

KLOW additionally contains KPV, whereas GLOW contains BPC-157, full-length thymosin beta-4 (sold here as TB-500) and GHK-Cu. No head-to-head study has compared the blends, so their compositional difference should not be presented as evidence of different biological effects.

What is GLOW's labelled composition, and what did the published assays measure?

GLOW is labelled as 70 mg total: 50 mg GHK-Cu, 10 mg BPC-157 and 10 mg full-length thymosin beta-4 (43 amino acids, sold here as TB-500). This is the nominal label composition, not exact measured content. The manufacturer-submitted Janoshik report measured 46.38 mg, 11.29 mg and 10.05 mg respectively; the shop-commissioned Liquilabs report measured 52.6 mg, 15.56 mg and 8.68 mg respectively. Each report describes the submitted sample and does not establish the content of every vial.

Does GLOW have a shop-commissioned, blend-level lab report in addition to the manufacturer-submitted report?

Yes. Both published reports cover finished-blend samples. The Green-batch Janoshik report was submitted through the manufacturer, while the shop separately commissioned Liquilabs report LYO-0261. Only the Liquilabs report should be described as commissioned by the shop; neither report should be characterised as testing only the raw component peptides. The certificates, measurements and verification links are listed at /coa.

Are there clinical studies on GLOW?

Not for the specific blend. BPC-157 evidence is overwhelmingly preclinical, with only very limited human data. Full-length thymosin beta-4 has been examined in some early-phase human trials for wound and tissue repair, and GHK-Cu has small topical cosmetic studies, but none of that work tested the GLOW blend or validates it. Treat GLOW as a research material whose combined behaviour has not been clinically studied.

Is GLOW legal to purchase for laboratory research in the EU?

None of the three components holds an EU marketing authorisation as a medicinal product, so GLOW cannot be marketed as a medicine. It is sold strictly as a research chemical for laboratory use, not as a medicine, supplement or product for human consumption. Purchase, import and research rules can vary by member state, so researchers should confirm the current status in their own country before ordering; this is not legal advice and does not claim that every possible use is or is not permitted.

Does BPC-157 have EU marketing authorisation or FDA approval in the US?

No. BPC-157 does not have EU marketing authorisation as a medicinal product and is not FDA-approved in the US. It remains an investigational compound studied almost entirely in preclinical models and has drawn regulatory scrutiny in some jurisdictions when marketed for human use outside a research context.

Does full-length thymosin beta-4 have EU marketing authorisation or FDA approval in the US?

No. Full-length thymosin beta-4, which is what GLOW's TB-500 component is, does not have EU marketing authorisation as a medicinal product and is not FDA-approved in the US. It has been investigated in early-phase clinical trials using clinical-grade, route-specific formulations; GLOW is supplied strictly as a research material, not a clinical-grade drug.

Is GHK-Cu approved as a medicine, or only used differently?

GHK-Cu does not have EU marketing authorisation as a medicinal product. It is widely used as an ingredient in cosmetic formulations, commonly marketed as "copper peptides", where its role in skin appearance is described in the cosmetic and dermatology literature summarised by reviews such as Pickart and Margolina. GLOW supplies GHK-Cu as an unformulated research-grade peptide for laboratory study, not as a finished cosmetic product.

What has preclinical research reported about BPC-157 tolerability?

In a dedicated preclinical toxicity study by Xu et al. involving mice, rats, rabbits and dogs, BPC-157 was reported as well tolerated at the doses and durations tested; many efficacy-focused injury-model reports came instead from the Sikiric group. These animal findings do not establish long-term or controlled human safety, which remains very limited. Any preclinical tolerability signal is hypothesis-generating for further research, not a safety guarantee.

Is there human safety data for TB-500 (thymosin beta-4)?

Full-length thymosin beta-4 has been evaluated for safety and tolerability in some early-phase (phase I and phase II) human trials, including topical and ophthalmic formulations, so it is not accurate to call it purely preclinical. However, those trials used clinical-grade formulations and specific routes that do not establish the safety of this research material or of the GLOW blend, and large controlled safety data at the amounts discussed in research protocols are lacking.

Can GHK-Cu cause irritation or other reactions in topical studies?

The human topical evidence for GHK-Cu is limited and comes mostly from small cosmetic studies rather than large controlled trials, and some frequently cited sources (such as Pickart and Margolina) are reviews rather than primary clinical studies. The available small human studies are insufficient to estimate an irritation incidence or a concentration-response relationship. Systemic administration in a research setting has a much smaller safety literature than the topical cosmetic use case.

Are there known interactions between the three peptides when combined in one blend?

No dedicated interaction studies exist for the three-component GLOW blend; the available data come from research on each component individually. Gene-expression profiling cited for this topic was conducted mainly with GHK in specific cultured cell lines. Researchers should treat the blend as its own experimental variable and should not infer interaction, additivity or human effects from the single-component literature.

How is GLOW different from buying BPC-157, TB-500 and GHK-Cu individually?

GLOW combines all three peptides pre-weighed into a single vial, so a protocol that calls for all three together does not require preparing and combining three separate stock solutions. PeptidesDirect also stocks BPC-157, TB-500 and GHK-Cu as standalone research peptides, which suits protocols that need to vary the ratio, study one component alone, or manage supply of a single component. The right choice depends on whether the design needs the fixed combination or the flexibility of separate vials.

How should reconstituted GLOW be stored, and how is degradation recognised?

Keep the reconstituted vial refrigerated, protected from light, and treat it as a short-lived working solution. There is no validated stability study defining a fixed usable window for the reconstituted GLOW blend, so rely on batch documentation rather than a set number of weeks. Visible cloudiness, colour change or particles are reasons to reject a vial, but their absence does not prove chemical integrity, because degradation can occur without a visible change.

Why is GLOW protected from light, and are BPC-157 or thymosin beta-4 relevant to anti-doping?

GHK-Cu is a copper-containing peptide, and light protection is applied as a precautionary storage condition rather than on the basis of a product-specific photostability study. Separately, on anti-doping: under the 2026 World Anti-Doping Agency Prohibited List, BPC-157 is placed under S0 (non-approved substances) and full-length thymosin beta-4 and its derivatives under S2.3, both prohibited at all times. That is a sport-specific classification, separate from GLOW's status as a research-only product not intended for any human use.

Buy GLOW: BPC-157, TB-500 and GHK-Cu Blend for Laboratory Research

GLOW is a three-component research peptide blend that combines BPC-157, TB-500 (full-length thymosin beta-4) and GHK-Cu in a single vial. The three compounds are studied separately, predominantly in preclinical models, in the context of collagen biology and tissue repair. The blend itself has not been studied as a combination, so this article covers the individual components and the practical points of quality, storage and sourcing.

GLOWregeneration

3-in-1 skin peptide blend: GHK-Cu 50mg + BPC-157 10mg + TB-500 10mg. Targets collagen synthesis, tissue regeneration, and skin repair for comprehensive dermatological research.

For those looking to source GLOW for research purposes, here is everything essential: composition, scientific background and practical notes on quality, storage and sourcing.

What Is GLOW?

GLOW is sold as a proprietary peptide blend with a labelled total of 70 mg and a nominal composition of 50 mg GHK-Cu, 10 mg BPC-157 and 10 mg full-length thymosin beta-4. Its three components are:

BPC-157 (Body Protection Compound-157): A synthetic 15-amino-acid peptide described in the literature as a fragment of a reported gastric protein. It has been studied predominantly in preclinical models of tendon, muscle, bone and gastrointestinal injury (Sikiric et al.); this literature does not establish human efficacy.
TB-500 (full-length thymosin beta-4): A 43-amino-acid peptide with a central role in actin regulation. As supplied here it is the complete 43-aa thymosin beta-4 (CoA-confirmed); the name "TB-500" is also used in the market for a short Ac-LKKTETQ fragment, which is exactly why the certificate of analysis matters. Full-length thymosin beta-4 has been studied for cell migration and angiogenesis, particularly in wound-healing and cardiac-regeneration research (Goldstein et al., 2005).
GHK-Cu (Glycyl-L-Histidyl-L-Lysine-Copper): A copper complex of the tripeptide GHK. GHK itself occurs naturally and has been detected in human plasma, saliva and urine, and reported plasma GHK levels decline with age; those measurements concern GHK rather than the finished GHK-Cu material. GHK-Cu has been studied for effects on collagen-related gene expression and skin biology.

Why This Particular Combination?

Compared with KLOW, GLOW omits KPV. No head-to-head study has compared the two blends, and this compositional difference does not by itself establish a difference in biological effect.

The Research Foundation

BPC-157 and Tissue Repair: A 2025 systematic review by Vasireddi et al. in orthopaedic sports medicine found predominantly preclinical evidence for BPC-157 across musculoskeletal injury models (fractures, tendon ruptures, ligament injuries, muscle injuries) and did not establish human efficacy. Proposed mechanisms in that literature include VEGF upregulation, activation of the FAK-paxillin pathway and modulation of the NO system, studied in cell and animal models.

TB-500 (full-length thymosin beta-4) and Cell Migration: Full-length thymosin beta-4, the compound sold here as TB-500, is a principal actin-sequestering peptide in many eukaryotic cells. In cell and animal studies it has been reported to support new blood-vessel formation, modulate inflammation and assist migration of repair cells to sites of tissue damage.

GHK-Cu and Skin Biology: The narrative review by Pickart and Margolina (2018, International Journal of Molecular Sciences) summarises laboratory research on GHK-Cu and small topical cosmetic studies. It also discusses gene-expression analyses conducted mainly with GHK in specific cultured cell lines, not with the finished GHK-Cu material in humans. The human topical studies are too small and incompletely reported to establish clinical efficacy, tolerability rates or a concentration-response relationship.

Component Mechanisms (Studied Separately)

The mechanisms below come from research on each peptide individually, in cell culture or animal models. No study has tested how the three behave together in the GLOW blend, so these are separate, hypothesis-generating component findings, not evidence of a combined, complementary or additive effect:

BPC-157: reported effects on angiogenesis-related signalling and fibroblast migration in cell and animal models, and on collagen organisation in animal wound models.
Full-length thymosin beta-4 (TB-500): binds monomeric actin and regulates actin polymerisation; studied for effects on cell migration and new blood-vessel formation.
GHK-Cu: studied for effects on collagen-related gene expression and skin biology. Gene-expression profiling has been done largely on GHK in specific cultured cell lines (including cancer-cell lines), which does not translate directly to the finished GHK-Cu material or to humans.

Quality Criteria When Buying

For a multi-peptide blend, analytics are decisive. Researchers should look for the following criteria:

Which laboratory, and what was tested: The current GLOW documentation includes two reports on finished-blend samples: a manufacturer-submitted Janoshik report for the Green batch and a separate report commissioned by the shop from Liquilabs (batch LYO-0261). The commissioning routes differ, but neither report should be described as testing only the raw component peptides.
Per-component purity, identity and content: A useful certificate distinguishes HPLC purity, molecular identity and quantitative content for each component rather than treating combined vial weight as sufficient. The current certificates, reported measurements and verification links are listed on our lab-reports page at /coa.
Label claim versus measured content: The labelled recipe is 50 mg GHK-Cu, 10 mg BPC-157 and 10 mg full-length thymosin beta-4. The published Janoshik assay reports 46.38 mg, 11.29 mg and 10.05 mg respectively; the Liquilabs assay reports 52.6 mg, 15.56 mg and 8.68 mg. These results describe the submitted samples and should not be represented as exact confirmation of a 70 mg total or the nominal ratio.

Dose Figures Reported in the Literature

No dosing has been established for the GLOW blend as a whole, and the figures below are values reported in the underlying research (largely animal models), not usage recommendations for this product:

BPC-157: rodent studies (Sikiric et al.) administered it across a range of nanogram- and microgram-per-kilogram levels, by injection, without establishing a conventional dose-response relationship. These are animal figures and do not translate to human use.
TB-500 (full-length thymosin beta-4): research reports describe milligram-range amounts, but these come from animal work and early-phase clinical formulations that differ from this research material.
GHK-Cu: small topical studies used formulation-specific concentrations that were not consistently reported; they do not establish a systemic dose or a concentration-response relationship.

Any use of these numbers is a matter of the specific research design; they do not translate into a dose for the blend or for human use.

Storage and Handling

GLOW is supplied as a lyophilised powder:

Unopened: Store the lyophilised powder cold, ideally frozen, protected from light and repeated freeze-thaw cycles.
After reconstitution: Keep refrigerated and treat the reconstituted vial as a short-lived working solution. There is no validated stability study defining a fixed usable window for the reconstituted GLOW blend, so rely on the batch documentation rather than a fixed number of weeks.
Reconstitution: Use only a solvent and concentration validated for the specific analytical or in-vitro method. No product-specific reconstitution protocol has been validated for this blend.
Appearance is not a purity test: Visible cloudiness, discoloration or particles are reasons to reject a vial, but their absence does not prove chemical integrity, since peptide degradation can occur without a visible change.
Light protection: As a copper-containing peptide, GHK-Cu is kept protected from light as a precautionary storage condition. Use amber or foil-wrapped vials.

Why Buy GLOW from PeptidesDirect?

Documented certificates: Manufacturer-sourced per-batch analysis plus the shop-commissioned independent Liquilabs blend report, with verification links on our lab-reports page at /coa.
EU shipping: Shipped from within the EU. Deliveries within the EU customs and VAT territories generally do not incur customs duties or import VAT; special territories, including the Canary Islands and Åland, can require customs formalities and local import taxes.
Delivery time: 2-3 business days with tracking.

The current GLOW 70 mg price is shown on the product page linked below.

Frequently Asked Questions